b56cf440-eb3a-872d-3728-16f8b17d42ae flex-box container between col-100 0
f73b56e9-3a53-9379-0912-80a762f8c45b flex-box col-100 0
262fa7d7-4358-ae73-937d-5d70d48b348a col-100 0
Transforming ILD Services
Influencing in Action
9645a91d-2549-dcb5-ce4a-bc6725a42ab3 flex-box container between col-100 0
fbcdba4b-9f02-dcdd-61a1-ea89b75a6b2d flex-box col-50 0
f344ab39-ea12-2cf7-f7c6-3eb698c1a248 col-100 0
Our influencing work is putting the 'Action' in 'Action for Pulmonary Fibrosis'. We understand just how urgently change is needed for PF care in the UK.
We're dedicated to working alongside all members of the PF community to shape and inform decision-making that impacts you.
de2ad2bf-dd57-30d8-e146-3f00eff5e9a9 flex-box col-50 1
a52fb2bb-65f9-9907-9175-e9746b9d29d8 col-100 0
9bd58d77-d2ae-6eb1-39c4-954e5be8a0c8 flex-box container between col-100 0
e57f18a1-e0af-fc0b-ac43-b2bbf596c815 flex-box col-100 0
705a8890-51da-38bf-388e-3fef7a3c7172 col-100 0
NHS Pathway Collaborators
If you haven’t already read about our Integrated Care Pathway for ILD services, which will transform the future of PF care, please find further information here.
Developing a fit-for-purpose ILD service could not have been possible without the input of a lived experience panel. Likewise, transforming services will require close collaboration with those providing care.
We’re already working with healthcare professionals across England to pilot the pathway and improve ILD services. APF's involvement will ensure that lived experience stays at the heard of all changes.
We’re attending regular meetings with ILD networks across these regions to help shape and inform decision-making, ensuring the lived experience and patient needs are at the heart of future services.
ecc0515b-45ff-6b2a-ee51-e4de2c2b4653 col-100 1
Keep an eye on our News pages for updates and activities from these services!
e603249a-ef40-d098-0263-4c02b18881c6 flex-box container between col-100 0
dd397078-53c5-63c0-379d-d635c6477907 flex-box col-100 0
54a1e224-1de9-9f3f-af85-8098ad0135ff col-100 0
APF In Parliament
579372eb-e3f5-41c7-f8da-229e9b636a14 flex-box col-50 1
27f41555-522e-81c5-7ac6-65a3fdc02798 col-100 0
One of the most heard concerns we hear from members of the PF community is that they, their healthcare provider, and/or those close to them had never heard of PF before their diagnosis.
Awareness of PF in the UK is low, so last year (November 2023) we made the first move to put PF on the parliamentary agenda.
7e394a22-680d-69cc-49dd-265ae60321a4 col-100 1
Thanks to our supporters, every MP in parliament received an email invite to attend our event, putting our cause directly into each MP’s inbox!
34 MPs attended the event to learn more about PF and how they can help to shape change.
Read our news piece of the event here
33b446b6-34f5-96d9-a151-457b1d3883d9 flex-box col-50 1
56f8849e-91fe-4897-51ef-8c6676b5ad17 col-100 0
38c143d9-0e31-6568-cc9b-1d91b6ba81ba flex-box container between col-100 0
2a92581e-ac07-0200-5b27-73a6201fd43c flex-box col-100 0
5bc648c0-e3aa-2e75-52de-804e1278c805 col-100 0
APF and COVID-19
The COVID-19 pandemic had a huge impact on the lives and care of those with PF. Public health protections were put in place for many groups with conditions that made them especially vulnerable to COVID-19 infection, but PF was not one of them.
b4188731-53b4-1d5e-a30a-2823de1bb45f col-100 1
Our support lines overflowed with calls from those who were intensely concerned for the future of their treatment and potential access to transplant surgery but didn’t feel seen or heard by the Government.
We used our platform to highlight the urgent health needs of those with PF, and in May 2020 provided written evidence to the Health and Social Care committee in Parliament, outlining the impact of COVID-19 on addressing these needs.
0959c131-b288-a43d-1ede-a778d06d18a8 flex-box container between col-100 0
b3dd5714-d2d2-e3df-d302-9aaa1bb8b3a2 flex-box col-100 0
0cf7814f-4ed0-311e-c0b8-ec5a4a55234f col-100 0
Access to Antifibrotics Campaign
91dc151e-fc52-499e-d6c9-2fd9c5d7686a flex-box col-50 1
1b0adff2-1f28-725d-08fb-9d502a00068f col-100 0
One of the biggest developments for PF treatment was has been the approval of antifibrotic drugs. However, initial guidelines were so restricted that most patients were not able to access the life-lengthening treatment.
Pirfenadone and Nintedanib can slow the progression of lung fibrosis. Both were approved as a PF treatment in 2022, following 5 years of campaigning by APF, but was only available for patients whose lung function had declined below 80%.
df493328-a6dc-b901-6df0-8d44a199c8e5 col-100 1
This approach, forcing patients to wait until their condition had worsened before they could access treatment, is not one that would ever be seen for cancers or other life-limiting conditions. Recognising this inequality, APF set out to make change.
We worked together with clinicians and patients to urge decision-makers to fast-track the guideline review to allow more people with PF to access life-lengthening antifibrotic treatment sooner. We worked together with clinicians and patients to urge decision-makers to fast-track the guideline review to allow more people with PF to access life-lengthening antifibrotic treatment sooner.
Read more about our work to widen antifibrotic access here
343c9489-9e95-8494-6ec8-095967c2b116 flex-box col-50 2
b5e4d927-61c7-bfb4-03b5-44f674bf1c8c col-100 0
8360d853-a380-b16d-9d90-357073d0378f flex-box col-100 3
0b531e13-15ca-e6f4-266d-eb3cc4f915cb col-100 0
Not found what you were looking for?
Get in touch with the team at policy@actionpf.org
Tab ID:269